Search Weight Loss Topics:

Home » Long Term Weight Loss » Weight-loss drug works but has safety risks, FDA says

WASHINGTON — Federal health officials continue to voice safety concerns over an experimental diet pill from drugmaker Vivus Inc., which will make its second attempt to convince experts of the drugs' safety next week. The drug Qnexa helped people lose weight but may cause long-term health problems in overweight and obese patients, Food and Drug Administration reviewers said.

Don't miss these Health stories

Hospitals scramble for scarce kids' cancer drug

An Ohio drugmaker began releasing limited supplies of a crucial medication to treat childhood leukemia Thursday, sending hospital pharmacists facing life-threatening shortages scrambling for their share.

High arsenic levels found in some organic foods, baby formula Amid shortages, hospitals trash scarce drugs Star Jones on her weight loss: 'I wasn't plus-size. I was morbidly obese' Short-term pollution triggers heart attack, stroke

The FDA staff will ask an advisory panel to consider whether the drug's benefits for obese patients will outweigh its risk of birth defects and heart problems.

In documents posted online on Friday, FDA reviewers said patients taking Qnexa during a clinical trial lost more weight, and kept it off for longer, than patients taking a placebo, or sugar pill. These patients also had lower levels of problems associated with obesity, such as issues with blood pressure and blood sugar.

However, patients taking the drug had more safety problems than patients on a placebo, including memory loss and birth defects, and these problems could get worse over time.

Qnexa is a combination of appetite suppressant phentermine and anti-seizure drug topiramate.

A company study in December showed topiramate caused a higher rate of oral clefts in infants of women taking the drug during pregnancy, and the company said it would limit Qnexa to women who are not pregnant.

The FDA already rejected Qnexa in 2010 because of safety concerns -- including elevated heart rate in some users and the potential for birth defects if pregnant women used the drug.

Vivus resubmitted its application in October, proposing to limit the drug to only women who cannot have children. In January, the company broadened the label to just limit pregnant women from taking the drug, in response to an FDA request.

An advisory panel of outside experts will vote Feb. 22 on whether to recommend the drug. The group's recommendation is not binding, and the FDA is expected to make its final decision by April 17.

The Associated Press and Reuters contributed to this report

Follow this link:
Weight-loss drug works but has safety risks, FDA says

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)	30313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120
Select Your US State	Select Your StateAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyoming
Program Choice	Select Your ProgramInjectable HGHInjectable TestoteroneInjectable SermorelinInjectable Weight LossInjectable HCG DietInjectable Vitamins
Confirm over 30 years old	Yes
Confirm that you resident in USA	Yes
This is a Serious Inquiry	Yes
Message:

Home » Long Term Weight Loss » Weight-loss drug works but has safety risks, FDA says